Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin DDI with Mefenamic Acid
NCT03070678Phase 1Completed
- Sponsor
- Sanofi
- Start
- Mar 2017
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sotagliflozin in diabetes mellitus (DM), sponsored by Sanofi. Primary endpoints: Maximum Plasma Concentration up to 144 hours, Area Under the Concentration-Time Curve from 0 to Last Quantifiable Concentration up to 144 hours and 1 more. Started Mar 2017; status: completed.
02
Drugs
sotagliflozin
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT03070678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03070678.